Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
77.49
+4.16 (5.67%)
At close: Jun 9, 2026, 4:00 PM EDT
75.31
-2.18 (-2.81%)
Pre-market: Jun 10, 2026, 6:23 AM EDT

Corcept Therapeutics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Corcept Therapeutics stock has a consensus rating of "Buy" and an average price target of $88. The average 1-year stock price forecast is 13.56% higher than the current stock price, while the lowest is $50 (-35.48%) and the highest is $135 (+74.22%).

Price Target: $88 (+13.56%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$50$88$88$135
Change-35.48%+13.56%+13.56%+74.22%

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy333344
Buy111111
Hold112211
Sell000000
Strong Sell110000
Total666666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Piper Sandler
Piper Sandler
Buy
Reiterates
$88
BuyReiterates$88+13.56%Jun 1, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$95
BuyReiterates$95+22.60%Jun 1, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$110$135
BuyReiterates$110$135+74.22%May 28, 2026
UBS
UBS
Buy
Upgrades
$72
BuyUpgrades$72-7.08%May 13, 2026
Wolfe Research
Wolfe Research
Hold
Upgrades
n/a
HoldUpgradesn/an/aMar 26, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
988.62M
from 761.41M
Increased by 29.84%
Revenue Next Year
1.40B
from 988.62M
Increased by 41.62%
EPS This Year
0.49
from 0.82
Decreased by -40.55%
EPS Next Year
2.50
from 0.49
Increased by 411.79%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
365.98M401.86M482.38M675.04M761.41M988.62M
Revenue Growth
3.42%9.80%20.04%39.94%12.79%29.84%
Gross Profit
360.70M396.47M475.89M664.16M748.43M971.80M
Gross Margin
98.56%98.66%98.66%98.39%98.30%98.30%
Operating Income
124.48M112.63M107.28M136.95M44.80M91.45M
Net Income
112.51M101.42M106.14M141.21M99.65M85.73M
EPS
----0.820.49
EPS Growth
-----33.33%-40.55%
Forward PE
21.0119.9532.6132.1155.53158.95
Free Cash Flow
120.18M115.55M128.39M183.85M114.19M108.00M
No. Analysts
-----5
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.0B
Avg988.6M
Low918.8M

Revenue Growth

Revenue Growth202620272028
High
34.7%
Avg
29.8%
Low
20.7%

EPS Forecast

EPS202620272028
High-
Avg0.49
Low-

EPS Growth

EPS Growth202620272028
High-
Avg
-40.5%
Low-